prostate-cancer-calculator

Clinical decision support for prostate cancer: risk stratification (NCCN/EAU/CAPRA), LNI prediction (Briganti/Roach), PSADT/BCR assessment, salvage RT planning, and Polish NFZ drug programmes (B.56 for apalutamide/darolutamide/enzalutamide/olaparib/niraparib/talazoparib, C.87 for abiraterone). Covers mHSPC, nmCRPC, mCRPC eligibility, qualification criteria, dosing, and monitoring.